睿知中国医院研究地图
候选清单

南京

东南大学附属中大医院

Zhongda Hospital, Southeast University

在本站收录的 53 种疾病中,这家医院列在其中 18 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

东南大学附属中大医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 食管鳞状细胞癌Oesophageal squamous cell carcinoma18 篇牵头论文
  2. 肝细胞癌Hepatocellular carcinoma59 篇牵头论文牵头 9 项开放试验
  3. 胃癌Stomach cancer21 篇牵头论文牵头 1 项开放试验
  4. 视网膜母细胞瘤Retinoblastoma1 篇牵头论文
  5. 脊索瘤Chordoma0 篇牵头论文
  6. 骨肉瘤Osteosarcoma3 篇牵头论文
  7. 胃肠道间质瘤Gastrointestinal stromal tumour1 篇牵头论文
  8. 神经母细胞瘤Neuroblastoma2 篇牵头论文
  9. 尤文肉瘤Ewing sarcoma2 篇牵头论文
  10. 多发性骨髓瘤Multiple myeloma4 篇牵头论文
  11. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia0 篇牵头论文
  12. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura1 篇牵头论文
  13. 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文
  14. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis1 篇牵头论文
  15. 法布雷病Fabry disease0 篇牵头论文
  16. IgA 肾病IgA nephropathy3 篇牵头论文
  17. 原发性胆汁性胆管炎Primary biliary cholangitis1 篇牵头论文
  18. 先天性膈疝Congenital diaphragmatic hernia1 篇牵头论文

未列出的收录疾病:鼻咽癌、肝母细胞瘤、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性硬化性胆管炎、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 18 篇,占 0.6%。

牵头论文
18
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 3320222023: 5520232024: 4420242025: 332025

南京有 5 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题早期发现与内镜影像与人工智能放疗
论文中的科室消化/肝病科肿瘤内科影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文18
  1. Knockdown of WISP1/DKK1 restrains phenotypic plasticity in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition and stemness.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  2. Cervical Incision-Free Technique for R0 Resection in Cervicothoracic Esophageal Carcinoma: A Novel Approach of the Chai's Supra-Thoracic Apex Technique.2025Journal of laparoendoscopic & advanced surgical techniques. Part A
  3. Bioinformatics analysis to identify endocrine-disrupting chemicals targeting key ESCC-related genes.2025Toxicology mechanisms and methods
  4. Synergism of Fusobacterium periodonticum and N-nitrosamines promote the formation of EMT subtypes in ESCC by modulating Wnt3a palmitoylation.2024Gut microbes免费全文
  5. A novel upregulated hsa_circ_0032746 regulates the oncogenesis of esophageal squamous cell carcinoma by regulating miR-4270/MCM3 axis.2024Human genomics免费全文
  6. The role of JMJD2A in immune evasion and malignant behavior of esophageal squamous cell carcinoma.2024International immunopharmacology
  7. Artificial intelligence enhances the management of esophageal squamous cell carcinoma in the precision oncology era.2024World journal of gastroenterology免费全文
  8. LINC01116 modulates EMT process via binding with AGO1 mRNA in oesophageal squamous cell carcinoma.2023Biochimica et biophysica acta. Molecular cell research
  9. Artificial intelligence assisted cytological detection for early esophageal squamous epithelial lesions by using low-grade squamous intraepithelial lesion as diagnostic threshold.2023Cancer medicine免费全文
  10. Analysis of white-light imaging-based features predictive for determination of lesion depths of superficial flat esophageal squamous cell carcinoma: a retrospective multicenter study from China.2023European journal of medical research免费全文
  11. Role of interferon alpha-inducible protein 6 in modulating the proliferation, apoptosis and senescence of oesophageal squamous cell carcinoma cells.2023Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  12. Insulin-like growth factor-2 mRNA-binding protein 3 promotes cell migration, invasion, and epithelial-mesenchymal transition of esophageal squamous cell carcinoma cells by targeting zinc finger E-box-binding homeobox 1 mRNA.2023Molecular carcinogenesis
  13. SIRT3 Promotes the Development of Esophageal Squamous Cell Carcinoma by Regulating Hexokinase 2 through the AKT Signaling Pathway.2022Bulletin of experimental biology and medicine
  14. LncRNA SNHG16 promotes development of oesophageal squamous cell carcinoma by interacting with EIF4A3 and modulating RhoU mRNA stability.2022Cellular & molecular biology letters免费全文
  15. A Rapid Cytological Screening as pre-Endoscopy Screening for Early Esophageal Squamous Cell Lesions: A Prospective Pilot Study from a Chinese Academic Center.2022Technology in cancer research & treatment免费全文
  16. Construction and Validation of an Immune-Related Gene Prognostic Index for Esophageal Squamous Cell Carcinoma.2021BioMed research international免费全文
  17. Ultrasound-Stimulated Microbubbles Inhibit Aggressive Phenotypes and Promotes Radiosensitivity of esophageal squamous cell carcinoma.2021Bioengineered免费全文
  18. Biological and clinical implications of metastasis-associated circular RNAs in oesophageal squamous cell carcinoma.2021FEBS open bio免费全文
中文论文(未计入)1
  1. [Efficacy and safety of endoscopic submucosal dissection with additional radiotherapy for T1a-MM/T1b-SM esophageal squamous cell carcinoma].2023Zhonghua yi xue za zhi
PubMed 以外找到的论文(未计入)5
  1. 271O Final analysis and biomarker evaluation of JUPITER-06: A phase III trial of toripalimab plus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma2025Annals of Oncology论文
  2. Minimally Invasive Inflatable Mediastinoscope-Assisted Laparoscopic Esophagectomy for Esophageal Cancer: Case Series and Review2025American Journal of Clinical and Experimental Medicine论文
  3. Surgical Management of Upper Thoracic Esophageal Squamous Cell Carcinoma with Concomitant Hypersplenism: Integration of Chai's Supra-Thoracic Apex Technique with Laparoscopic Splenectomy - A Technical Innovation Case Study with Systematic R2025International Journal of Surgery & Surgical Techniques综述
  4. 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)2021Annals of Oncology论文
  5. First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.2021Journal of Clinical Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 59 篇,占 0.4%。

牵头论文
59
2021–2025 年
牵头试验
33
任何状态,ClinicalTrials.gov
牵头的开放试验
9
正在或即将招募
作为研究中心的开放试验
6
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 111120222023: 8820232024: 121220242025: 17172025

南京有 7 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

这家医院参与的开放试验 15

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma
    分期
    未注明
    开始
    2026-01
    登记号
    NCT07351669

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:东南大学附属中大医院南京

  2. 正在招募
    SIRT Versus cTACE for Unresectable HCC (CHANCE2506)
    分期
    不分期
    开始
    2025-04
    登记号
    NCT06909708

    年龄 18 岁 至 未注明(登记的条件)

    牵头:东南大学附属中大医院南京

  3. 正在招募
    Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma
    分期
    不分期
    开始
    2024-02
    登记号
    NCT06694636

    年龄 25 岁 至 75 岁(登记的条件)

    牵头:东南大学附属中大医院南京

  4. 正在招募
    Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data
    分期
    未注明
    开始
    2024-12
    登记号
    NCT06849180

    年龄 18 岁 至 未注明(登记的条件)

    牵头:东南大学附属中大医院南京

  5. 正在招募
    DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC
    分期
    不分期
    开始
    2023-12
    登记号
    NCT06190665

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:东南大学附属中大医院;另有 1 家列出的医院为研究中心北京、南京

  6. 正在招募
    Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC
    分期
    未注明
    开始
    2018-06
    登记号
    NCT06876753

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:东南大学附属中大医院南京

  7. 即将招募
    Heterogeneity of Treatment Effects of Adding Locoregional Therapies to Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma (ISMIO-026)
    分期
    未注明
    开始
    2026-09
    登记号
    NCT07824765

    年龄 18 岁 至 未注明(登记的条件)

    牵头:东南大学附属中大医院南京

  8. 即将招募
    TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)
    分期
    未注明
    开始
    2026-09
    登记号
    NCT07836309

    年龄 16 岁 至 未注明(登记的条件)

    牵头:东南大学附属中大医院南京

  9. 即将招募
    EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial
    分期
    I/II期
    开始
    2025-09
    登记号
    NCT07187284

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:东南大学附属中大医院南京

  10. 正在招募
    A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.
    分期
    II/III期
    开始
    2025-03
    登记号
    NCT06844357

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心南京

  11. 正在招募
    GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
    分期
    II期
    开始
    2025-11
    登记号
    NCT07209813

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心北京、南京、南昌、杭州、郑州、长沙

  12. 正在招募
    MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
    分期
    I期
    开始
    2025-08
    登记号
    NCT07391839

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 8 家列出的医院为研究中心上海、南京、合肥、广州、杭州、济南、福州、郑州

  13. 正在招募
    A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
    分期
    III期
    开始
    2024-08
    登记号
    NCT06371157

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心南京、杭州、郑州、长沙

  14. 即将招募
    A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
    分期
    III期
    开始
    2026-11
    登记号
    NCT07691762

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、南京

  15. 即将招募
    A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
    分期
    III期
    开始
    2025-01
    登记号
    NCT06779461

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心上海、兰州、南京、天津、广州、蚌埠、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题局部治疗(消融、TACE、HAIC)复发与预后影像、人工智能与早期发现
论文中的科室影像/核医学科普外/肝胆胰外科肿瘤内科放疗科
牵头的论文59
  1. The METAL Score for Early Stratification of Radiological Response and Survival in Hepatocellular Carcinoma Treated with TACE and Immunotherapy Combinations.2026Academic radiology
  2. Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204).2026Hepatology (Baltimore, Md.)免费全文
  3. BRIX1 activated by mTORC1-SP1 signaling regulates ribosome biogenesis and alternative splicing to promote hepatocellular carcinoma progression.2026Hepatology international
  4. Inhibition of the U12-type splicing factor ZCRB1 mediates retention of the USP21 minor intron to suppress malignant progression in hepatocellular carcinoma.2026Hepatology international
  5. Identification of a Novel TIM-3 Targeting Peptides Probe to Indicate the Immunomodulation of SBRT Combined with Anti-TIM-3 Therapy in HCC.2026Molecular imaging and biology
  6. LI-RADS Nonradiation Treatment Response Algorithm Version 2024: Diagnostic Performance and Impact of Ancillary Features.2025AJR. American journal of roentgenology
  7. Dynamic changes of radiological and radiomics patterns based on MRI in viable hepatocellular carcinoma after transarterial chemoembolization.2025Abdominal radiology (New York)
  8. The nVR model: prediction of LI-RADS treatment response nonviable recurrence of hepatocellular carcinoma after primary transarterial chemoembolization.2025Abdominal radiology (New York)
  9. Tailored Liposomal Nanomedicine Suppresses Incomplete Radiofrequency Ablation-Induced Tumor Relapse by Reprogramming Antitumor Immunity.2025Advanced healthcare materials
  10. Arginine-Loaded Nano-Calcium-Phosphate-Stabilized Lipiodol Pickering Emulsions Potentiates Transarterial Embolization-Immunotherapy.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  11. Risk Factors and Survival Analysis of Spontaneously Ruptured Hepatocellular Carcinoma: A Retrospective Cohort Study in Bilateral Centers.2025Annals of surgical oncology
  12. Elucidating the role of AC026412.3 in hepatocellular carcinoma: a prognostic disulfidptosis-related LncRNAs model perspective.2025BMC gastroenterology免费全文
  13. FOXM1 promotes malignant biological behavior and metabolic reprogramming by targeting SPINK1 in hepatocellular carcinoma and affecting the p53 pathway.2025Biochimica et biophysica acta. Molecular basis of disease
  14. Pickering emulsion with tumor vascular destruction and microenvironment modulation for transarterial embolization therapy.2025Biomaterials
  15. Co-delivery of SN38 and MEF2D-siRNA via tLyp-1-modified liposomes reverses PD-L1 expression induced by STING activation in hepatocellular carcinoma.2025Colloids and surfaces. B, Biointerfaces
  16. Radiosensitization strategies for hepatocellular carcinoma: Mechanisms, therapeutic advances, and clinical perspectives.2025Critical reviews in oncology/hematology
  17. Development of a PPP1R14B-associated immune prognostic model for hepatocellular carcinoma.2025European journal of medical research免费全文
  18. A nationwide investigation on imaging follow-up after Locoregional therapy for hepatocellular carcinoma in China: Current practices and challenges.2025European journal of radiology
  19. Machine learning and multi-omics characterization of SLC2A1 as a prognostic factor in hepatocellular carcinoma: SLC2A1 is a prognostic factor in HCC.2025Gene
  20. DiabetesLiver score: A non-invasive algorithm for advanced liver fibrosis and liver-related outcomes in type 2 diabetes mellitus population.2025Med (New York, N.Y.)
  21. MEG3 rs7158663 genetic polymorphism is associated with the risk of hepatocellular carcinoma.2025Nucleosides, nucleotides & nucleic acids
  22. Combination locoregional and systemic therapies in hepatocellular carcinoma.2025The lancet. Gastroenterology & hepatology
  23. Dual-Synergistic Nanomodulator Alleviates Exosomal PD-L1 Expression Enabling Exhausted Cytotoxic T Lymphocytes Rejuvenation for Potentiated iRFA-Treated Hepatocellular Carcinoma Immunotherapy.2024ACS nano
  24. Diagnostic performance of MRI for residual or recurrent hepatocellular carcinoma after locoregional treatment according to contrast agent type: a systematic review and meta‑analysis.2024Abdominal radiology (New York)
  25. Predicting cachexia in hepatocellular carcinoma patients: a nomogram based on MRI features and body composition.2024Acta radiologica (Stockholm, Sweden : 1987)
  26. Study on the mechanism of liver cancer immune escape mediated by MINDY1 through regulation of PD-L1 ubiquitination level.2024Biomolecules & biomedicine免费全文
  27. Transarterial Chemoembolization with Epirubicin-Loaded Microspheres for Hepatocellular Carcinoma: A Prospective, Single-Arm, Multicenter, Phase 2 Study (STOPPER Trial).2024Cardiovascular and interventional radiology免费全文
  28. Functional Liver Imaging Score Derived from Gadoxetic Acid-enhanced MRI Predicts Cachexia and Prognosis in Hepatocellular Carcinoma Patients.2024Current medical science
  29. Single-cell landscape identifies the immunophenotypes and microenvironments of HBV-positive and HBV-negative liver cancer.2024Hepatology communications免费全文
  30. Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213).2024Journal of cachexia, sarcopenia and muscle免费全文
  31. MRI-Based Radiomics and Deep Learning in Biological Characteristics and Prognosis of Hepatocellular Carcinoma: Opportunities and Challenges.2024Journal of magnetic resonance imaging : JMRI
  32. TPA: Two-stage progressive attention segmentation framework for hepatocellular carcinoma on multi-modality MRI.2024Medical physics
  33. Prognostic difference between surgery and external radiation in patients with stage I liver cancer based on competitive risk model and conditional survival rate.2024PloS one免费全文
  34. Locoregional therapies for hepatocellular carcinoma: The current status and future perspectives.2024United European gastroenterology journal免费全文
  35. GBAP1 functions as a tumor promotor in hepatocellular carcinoma via the PI3K/AKT pathway.2023BMC cancer免费全文
  36. LncRNA HClnc1 facilitates hepatocellular carcinoma progression by regulating PKM2 signaling and indicates poor survival outcome after hepatectomy.2023Cancer medicine
  37. Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study.2023European radiology免费全文
  38. Letter to the editor: Hepatitis B virus reactivation in immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma.2023Hepatology (Baltimore, Md.)
  39. Irradiation stent with 125 I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: a multicenter randomized trial.2023International journal of surgery (London, England)RCT免费全文
  40. Hepatocellular Brg1 promotes CCl4-induced liver inflammation, ECM accumulation and fibrosis in mice.2023PloS one免费全文
  41. Predicting Microvascular Invasion in Hepatocellular Carcinoma Using CT-based Radiomics Model.2023Radiology
  42. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001).2023Signal transduction and targeted therapy免费全文
  43. ASO Author Reflections: Preoperative Microvascular Invasion Prediction to Assist in Surgical Plan for Single Hepatocellular Carcinoma-A Better Algorithm of Necessity.2022Annals of surgical oncology
  44. Preoperative Microvascular Invasion Prediction to Assist in Surgical Plan for Single Hepatocellular Carcinoma: Better Together with Radiomics.2022Annals of surgical oncology
  45. Exosome-transmitted circ_002136 promotes hepatocellular carcinoma progression by miR-19a-3p/RAB1A pathway.2022BMC cancer免费全文
  46. I-125 seeds brachytherapy with transcatheter arterial chemoembolization for subcapsular hepatocellular carcinoma.2022BMC gastroenterology免费全文
  47. Postoperative survival analysis of hepatocellular carcinoma patients with liver cirrhosis based on propensity score matching.2022BMC surgery免费全文
  48. Circular RNA hsa_circ_0032683 inhibits the progression of hepatocellular carcinoma by sponging microRNA-338-5p.2022Bioengineered免费全文
  49. Identification of HLA-A2 restricted epitopes of glypican-3 and induction of CTL responses in HLA-A2 transgenic mice.2022Cancer immunology, immunotherapy : CII免费全文
  50. TACE with dicycloplatin in patients with unresectable hepatocellular carcinoma: a multicenter randomized phase II trial.2022European radiologyRCT
  51. Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma.2022Investigational new drugs
  52. Safety and immunogenicity of COVID-19 vaccination in patients with hepatocellular carcinoma (CHESS-NMCID 2101): A multicenter prospective study.2022Journal of medical virology免费全文
  53. Target and drug predictions for SARS-CoV-2 infection in hepatocellular carcinoma patients.2022PloS one免费全文
  54. Circular RNA circ_0008274 upregulates granulin to promote the progression of hepatocellular carcinoma via sponging microRNA -140-3p.2021Bioengineered免费全文
  55. I125 irradiation stent for treatment of hepatocellular carcinoma with portal vein thrombosis: A meta-analysis.2021Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
  56. Portal Vein Irradiation Stent Plus Chemoembolization versus External Radiotherapy Plus Chemoembolization in Hepatocellular Carcinoma with Portal Vein Tumour Thrombus: A Retrospective Study.2021Cardiovascular and interventional radiology
  57. The clinical efficiency of TACE combined with simultaneous computed tomography-guided radiofrequency ablation for advanced hepatocellular carcinoma.2021Investigational new drugs
  58. Comparison of MRI and CT for the Prediction of Microvascular Invasion in Solitary Hepatocellular Carcinoma Based on a Non-Radiomics and Radiomics Method: Which Imaging Modality Is Better?2021Journal of magnetic resonance imaging : JMRI
  59. The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma.2021Targeted oncology
中文论文(未计入)2
  1. [Research progress of adjuvant TACE therapy for liver cancer after radical resection].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  2. [Research progress of prognostic analysis and clinicopathological characteristics of hepatoid adenocarcinoma of the stomach].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
它在 ClinicalTrials.gov 上的全部试验(任何状态)47
  1. Heterogeneity of Treatment Effects of Adding Locoregional Therapies to Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma (ISMIO-026)即将招募NCT07824765牵头方2026-09 启动
  2. TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)即将招募NCT07836309牵头方2026-09 启动
  3. A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma正在招募NCT07351669牵头方2026-01 启动
  4. SIRT Versus cTACE for Unresectable HCC (CHANCE2506)正在招募NCT06909708牵头方不分期2025-04 启动
  5. EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial即将招募NCT07187284牵头方I/II期2025-09 启动
  6. Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma正在招募NCT06694636牵头方不分期2024-02 启动
  7. Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data正在招募NCT06849180牵头方2024-12 启动
  8. DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC正在招募NCT06190665牵头方不分期2023-12 启动
  9. Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC正在招募NCT06876753牵头方2018-06 启动
  10. Development and Prospective Validation of a Heterogeneous Treatment Effect-Based Decision Model for Transarterial Chemoembolization Combined With or Without Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma已完成NCT07109336牵头方不分期2025-08 启动
  11. Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target Therapies状态不明NCT06607120牵头方2024-06 启动
  12. TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT.状态不明NCT06669377牵头方2024-01 启动
  13. TACE With Thermosensitive Nanogel Versus Embosphere for HCC状态不明NCT06593964牵头方不分期2024-09 启动
  14. WISH for Treatment Selection and Survival Prediction in Unresectable Hepatocellular Carcinoma已完成NCT07065786牵头方2024-01 启动
  15. Impact of Clinical Evident Portal Hypertension on HCC With TACE (CHANCE-CHESS 2301)状态不明NCT05703750牵头方2023-05 启动
  16. Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular Carcinoma状态不明NCT05957640牵头方I期2023-05 启动
  17. CT-based HVPG Assessment for Predicting the Prognosis of HCC With TACE (CHANCE-CHESS 2302)状态不明NCT05704192牵头方2023-05 启动
  18. TACE Combined With Penpulimab and Anlotinib for Advanced HCC状态不明NCT05344924牵头方II/III期2022-10 启动
  19. Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma状态不明NCT05280444牵头方II/III期2022-05 启动
  20. TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC已完成NCT05332821牵头方2022-12 启动
  21. Assessing the Prognosis of TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for HCC by Using Clinical and Imaging Biomarkers状态不明NCT05278195牵头方2022-04 启动
  22. TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC已完成NCT05332496牵头方2022-12 启动
  23. Lipiodol-TACE With Idarubicin Based On a Specific Emulsion Ratio for Hepatocellular Carcinoma状态不明NCT05631613牵头方2022-12 启动
  24. Efficacy and Safety of TACE in Combination With ICIs for HCC: a Real-world Study已完成NCT04975932牵头方2021-07 启动
  25. Tislelizumab in Combination With TACE in Advanced Hepatocellular Carcinoma状态不明NCT04652492牵头方II期2020-10 启动
  26. TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma状态不明NCT04559607牵头方不分期2020-09 启动
  27. Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001)进行中,不再招募NCT07204327牵头方2020-10 启动
  28. Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without TACE for Advanced HCC With Vascular Invasions已完成NCT06881446牵头方2018-06 启动
  29. Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without HAIC for Unresectable HCC With Portal Vein Tumor Thrombosis已完成NCT06881433牵头方2018-06 启动
  30. Irradiation Stent Placement Plus TACE for HCC and PVTT状态不明NCT03730675牵头方不分期2018-11 启动
  31. ISP-TACE Versus TACE for HCC With PVTT已完成NCT03108248牵头方2011-01 启动
  32. TACE With Dicycloplatin(TP21) in Unresectable HCC状态不明NCT05472896牵头方(推断)III期2022-06 启动
  33. Comparison of Liver and Renal Function After Transarterial Chemoembolization for Primary Hepatocellular Carcinoma With Iso-osmolar Contrast Media and Low Osmolar Contrast Media状态不明NCT01563484牵头方(推断)2012-03 启动
  34. A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma即将招募NCT07691762研究中心III期2026-11 启动
  35. GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma正在招募NCT07209813研究中心II期2025-11 启动
  36. A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.正在招募NCT06844357研究中心II/III期2025-03 启动
  37. MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.正在招募NCT07391839研究中心I期2025-08 启动
  38. A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma即将招募NCT06779461研究中心III期2025-01 启动
  39. A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma正在招募NCT06371157研究中心III期2024-08 启动
  40. Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere进行中,不再招募NCT06900543研究中心III期2025-04 启动
  41. Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma已完成NCT06310590研究中心I期2023-08 启动
  42. MANDARIN (S6371)已完成NCT05016245研究中心III期2021-09 启动
  43. To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer已终止NCT04520906研究中心不分期2020-12 启动
  44. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation已完成NCT04102098研究中心III期2019-12 启动
  45. STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma已完成NCT03113955研究中心不分期2017-10 启动
  46. Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC状态不明NCT02018757研究中心II期2014-01 启动
  47. Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using TACE With Antiangiogenesis状态不明NCT00518557研究中心不分期2007-04 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 21 篇,占 0.2%。

牵头论文
21
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 2220222023: 4420232024: 3320242025: 10102025

南京有 8 家医院列在胃癌下全国有 211 家医院列在胃癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    The Correlation Between Blood Concentration of Sintilimab and Efficacy and Adverse Reactions in Patients with Advanced Gastric Cancer
    分期
    未注明
    开始
    2023-02
    登记号
    NCT06702683

    年龄 18 岁 至 未注明(登记的条件)

    牵头:东南大学附属中大医院南京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题早期发现与内镜免疫与靶向药物腹膜转移与晚期
论文中的科室消化/肝病科肿瘤内科病理/检验科普外/肝胆胰外科
牵头的论文21
  1. Heterogeneity of T cells regulates tumor immunity mediated by Helicobacter pylori infection in gastric cancer.2025BMC cancer免费全文
  2. Epidemiology of Helicobacter pylori, gastric precancerous lesions and gastric cancer: a multicenter, population-based cross-sectional study in Nanjing.2025BMC infectious diseases免费全文
  3. Association between weight loss and survival outcomes in patients with gastric cancer: a meta-analysis.2025European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  4. Efficacy of human-derived fibrin sealant in preventing postoperative adverse events after gastric endoscopic submucosal dissection: a retrospective multicenter study.2025European journal of medical research免费全文
  5. Tumor-associated macrophage-derived exosome miR-194 confers cisplatin resistance in GC cells.2025European journal of medical research免费全文
  6. LncRNA BASP1-AS1 drives PCBP2 K115 lactylation to suppress ferroptosis and confer oxaliplatin resistance in gastric cancer.2025Free radical biology & medicine
  7. Clinical characteristics and prognostic factors of differentiated and undifferentiated early gastric cancer: A retrospective cohort study.2025Medicine免费全文
  8. Safety and efficacy of endoscopic resection for gastric gastrointestinal stromal tumors: a retrospective cohort study.2025Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  9. Unraveling the prognostic significance and molecular mechanisms of HKDC1 in cancer via integrated multi-omics and experimental validation.2025Pathology, research and practice
  10. Effects of polyunsaturated fatty acids on gastric cancer immunity and immunotherapy.2025Scientific reports免费全文
  11. Serum prealbumin level as a biomarker of survival outcomes in patients with gastric cancer: a meta-analysis.2024Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  12. Comprehensive evaluation of serum circHAS2 as a novel diagnostic and prognostic biomarker for gastric cancer.2024Molecular carcinogenesis
  13. Clinical value of serum polyunsaturated fatty acids in patients with gastric polyps.2024PeerJ免费全文
  14. A Novel Prognostic Biomarker CCR8 for Gastric Cancer and Anti-CCR8 Blockade Attenuate the Immunosuppressive Capacity of Tregs In Vitro.2023Cancer biotherapy & radiopharmaceuticals
  15. Comprehensive Analysis Based on the Cancer Immunotherapy and Immune Activation of Gastric Cancer Patients.2023Genetics research免费全文
  16. RHOJ Induces Epithelial-to-Mesenchymal Transition by IL-6/STAT3 to Promote Invasion and Metastasis in Gastric Cancer.2023International journal of biological sciences免费全文
  17. Clinical application and detection techniques of liquid biopsy in gastric cancer.2023Molecular cancer免费全文
  18. Molecular Characteristics, Clinical Significance, and Cancer Immune Interactions of Angiogenesis-Associated Genes in Gastric Cancer.2022Frontiers in immunology免费全文
  19. From part to whole, operative link on to endoscopic grading of gastric intestinal metaplasia, pathology to endoscopy: gastric intestinal metaplasia graded by endoscopy.2022Future oncology (London, England)
  20. A novel irradiation stent versus conventional irradiation stent for malignant dysphagia: A prospective randomized controlled trial.2021Journal of cancer research and therapeuticsRCT
  21. lncRNA NEAT1 regulates gastric carcinoma cell proliferation, invasion and apoptosis via the miR‑500a‑3p/XBP‑1 axis.2021Molecular medicine reports免费全文
中文论文(未计入)5
  1. [Applications and advances of artificial intelligence in gastric mucosal biopsy pathology].2025Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [Research on the evaluation of the efficacy of immunotherapy for gastric cancer by tertiary lymphoid structures].2025Zhonghua zhong liu za zhi [Chinese journal of oncology]
  3. [Efficacy of curative endoscopic submucosal dissection for patients with early cardia and non-cardia gastric cancer].2024Zhonghua yi xue za zhi
  4. [Efficacy of alternate mucosa-submucosa clip closure in preventing postoperative complications for patients with gastric mucosal lesions after endoscopic submucosal dissection].2024Zhonghua yi xue za zhi
  5. [Research progress of prognostic analysis and clinicopathological characteristics of hepatoid adenocarcinoma of the stomach].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. The Correlation Between Blood Concentration of Sintilimab and Efficacy and Adverse Reactions in Patients with Advanced Gastric Cancer正在招募NCT06702683牵头方(推断)2023-02 启动
  2. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  3. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer状态不明NCT04486651研究中心III期2020-09 启动
  4. Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center Study状态不明NCT03121729研究中心不分期2017-06 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

南京有 4 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年没有牵头脊索瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

南京有 4 家医院列在脊索瘤下全国有 84 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Survival analysis of patients with spinal chordomas.2019Neurosurgical review

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.1%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 222025

南京有 21 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

南京有 10 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室消化/肝病科
牵头的论文1
  1. Safety and efficacy of endoscopic resection for gastric gastrointestinal stromal tumors: a retrospective cohort study.2025Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

南京有 10 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

南京有 3 家医院列在尤文肉瘤下全国有 134 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.2%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 1120232024: 0020242025: 112025

南京有 7 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    分期
    I期
    开始
    2026-05
    登记号
    NCT07477587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛

  2. 正在招募
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    分期
    III期
    开始
    2022-10
    登记号
    NCT05552222

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、哈尔滨、天津、常州、广州、成都、杭州、武汉、沈阳、济南、深圳、温州、福州、西安、郑州、重庆、长春、长沙

  3. 即将招募
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-06
    登记号
    NCT07569757

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 38 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、徐州、成都、承德、昆明、杭州、株洲、沈阳、泸州、济南、湛江、石家庄、蚌埠、西安、贵阳、郑州、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层
论文中的科室肿瘤内科肾内科
牵头的论文4
  1. Nephrotic syndrome in a 51-year-old woman with light chain deposition disease.2025Ultrastructural pathology
  2. Clinical and cytogenetic characteristics of primary and secondary plasma cell leukemia under the new IMWG definition criteria: a retrospective study.2023Hematology (Amsterdam, Netherlands)
  3. Identification of hub genes with prognostic values in multiple myeloma by bioinformatics analysis.2021Hematology (Amsterdam, Netherlands)
  4. New insights into genetic characteristics between multiple myeloma and COVID-19: An integrative bioinformatics analysis of gene expression omnibus microarray and the cancer genome atlas data.2021International journal of laboratory hematology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma即将招募NCT07569757研究中心III期2026-06 启动
  2. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma正在招募NCT07477587研究中心I期2026-05 启动
  3. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma正在招募NCT05552222研究中心III期2022-10 启动
  4. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT06158841研究中心III期2024-05 启动
  5. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05083169研究中心III期2021-10 启动
  6. A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma已完成NCT04121260研究中心I期2019-12 启动
  7. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)已完成NCT03217812研究中心III期2017-11 启动
  8. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma已完成NCT03234972研究中心III期2017-11 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年没有牵头B 细胞急性淋巴细胞白血病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

南京有 3 家医院列在B 细胞急性淋巴细胞白血病下全国有 88 家医院列在B 细胞急性淋巴细胞白血病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的B 细胞急性淋巴细胞白血病开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL状态不明NCT04375683牵头方III期2020-03 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

南京有 3 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。

这些数字背后的记录
牵头的论文1
  1. Sudden coma at the onset of severe refractory thrombotic thrombocytopenic purpura with successful treatment.2021Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

南京有 13 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录
论文中的科室肾内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

南京有 8 家医院列在肌萎缩侧索硬化症下全国有 182 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

法布雷病

Fabry disease

2021–2025 年没有牵头法布雷病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

南京有 5 家医院列在法布雷病下全国有 80 家医院列在法布雷病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的法布雷病开放试验。

这些数字背后的记录
论文中的科室肾内科
中文论文(未计入)2
  1. [Characteristics of cardiac lesions in 17 patients with Fabry disease].2025Zhonghua xin xue guan bing za zhi
  2. [Analysis of a family with Fabry disease with 15 patients].2024Zhonghua nei ke za zhi

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.4%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

南京有 8 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
    分期
    III期
    开始
    2025-07
    登记号
    NCT06963827

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、包头、北京、南京、南昌、南通、厦门、宁波、广州、成都、无锡、杭州、济南、深圳、珠海、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肾内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

南京有 7 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性膈疝

Congenital diaphragmatic hernia

2021–2025 年中国大陆作者发表的 60 篇先天性膈疝 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

南京有 1 家医院列在先天性膈疝下全国有 44 家医院列在先天性膈疝下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性膈疝开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

东南大学附属中大医院

Zhongda Hospital, Southeast University

南京

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Zhongda Hospital; Zhongda Hospital Southeast University; Zhongda Hospital Affiliated to Southeast University; Zhongda Hospital Lishui Branch; Affiliated Zhongda Hospital of Southeast University; Zhongda Hospital of Southeast University; Nanjing Lishui People's Hospital (Zhongda Hospital Lishui Branch; Southeast University Affiliated Zhongda Hospital

提出更正下载数据